Jonathan Chang
Stock Analyst at Leerink Partners
(0.62)
# 4,014
Out of 4,966 analysts
88
Total ratings
29.73%
Success rate
-19.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Market Perform | $21 → $3 | $5.40 | -44.44% | 10 | Jul 22, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $33.10 | +126.59% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $24.87 | +8.56% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $32.22 | +129.67% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $8.95 | +22.97% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.33 | +313.63% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $7.11 | +954.85% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.38 | +577.51% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $37.97 | -20.99% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.77 | +577.97% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $7.32 | +4,681.42% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $5.09 | +410.81% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.06 | +4,993.38% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $7.90 | +254.43% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $8.13 | +551.91% | 7 | Aug 5, 2021 |
Replimune Group
Jul 22, 2025
Downgrades: Market Perform
Price Target: $21 → $3
Current: $5.40
Upside: -44.44%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $33.10
Upside: +126.59%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $24.87
Upside: +8.56%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $32.22
Upside: +129.67%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $8.95
Upside: +22.97%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.33
Upside: +313.63%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $7.11
Upside: +954.85%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.38
Upside: +577.51%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $37.97
Upside: -20.99%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.77
Upside: +577.97%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $7.32
Upside: +4,681.42%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $5.09
Upside: +410.81%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.06
Upside: +4,993.38%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $7.90
Upside: +254.43%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $8.13
Upside: +551.91%